Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trevi Therapeutics ( (TRVI) ) has issued an update.
On June 3, 2025, Trevi Therapeutics announced the pricing of its underwritten public offering of 17,400,000 shares of common stock at $5.75 per share, aiming to raise $100 million before expenses. The proceeds will fund clinical trials for Haduvio and support operational costs into 2029, but additional capital will be needed for full development and commercialization.
The most recent analyst rating on (TRVI) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.
Spark’s Take on TRVI Stock
According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.
Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.
To see Spark’s full report on TRVI stock, click here.
More about Trevi Therapeutics
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio, an investigational therapy for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio targets opioid receptors involved in the cough reflex arc.
Average Trading Volume: 2,497,238
Technical Sentiment Signal: Buy
Current Market Cap: $642.5M
Find detailed analytics on TRVI stock on TipRanks’ Stock Analysis page.